Redwood AI Bridges Markets and Medicine with DTC Eligibility and Pharma Partnership

Redwood AI gains DTC eligibility for US trading, partners with Resilience Biosciences on non-opioid pain therapies, and launches IR campaign to boost visibility.

Redwood AI is weaving together two distinct growth narratives this week, securing both a critical US trading upgrade and a high-stakes collaboration in drug discovery. The AI chemistry specialist has taken its first steps into the life sciences arena by teaming up with Resilience Biosciences to develop non-opioid therapeutics, while simultaneously clearing a major administrative hurdle for cross-border investors. The twin announcements signal a push to translate technical capability into commercial traction.

The partnership with Resilience Biosciences targets one of pharma's most intractable challenges: the search for alternatives to opioid-based pain management. Redwood AI brings its computational chemistry platform, cheminformatics tools and retrosynthesis engine to systematically generate drug derivatives, analyse patent landscapes and plan synthetic routes. The goal is to accelerate early-stage candidate identification and give scientific teams deeper insights into chemical space. For context, the AI-enabled drug discovery market is projected to exceed $50 billion by 2030, and the pressure on big pharma to shorten a decade-long, multibillion-dollar development cycle is mounting.

On the capital markets side, Redwood AI received eligibility for electronic settlement through the Depository Trust Company on May 27, 2026. The DTC clearance swaps physical stock certificates for electronic transfer between brokerages, a standard prerequisite for US-based institutional and retail investors trading on the OTCQB market. Chief executive Louis Dron expects the change to deepen liquidity and broaden the company's shareholder base, particularly among American accounts that previously faced friction in cross-border trades. The primary listing remains on the Canadian Securities Exchange.

To amplify its recent operational progress, Redwood AI has also engaged the InvestorBrandNetwork for an investor relations campaign running through September 30, 2026. The $114,000 cash outlay is designed to boost market visibility and draw attention to the company's artificial intelligence developments at a time when it is branching into new verticals.

The DTC milestone aligns with a broader push for market modernisation. On May 28, Broadridge Financial Solutions expanded its NYFIX platform to support overnight trading in over 4,000 US equities through its integration with Blue Ocean ATS. Meanwhile, the SEC is reportedly weighing new rules for tokenised versions of publicly traded shares. As the industry focuses on accessibility and liquidity for everything from NMS-listed stocks to OTC names, Redwood AI finds itself positioned at the intersection of infrastructure upgrades and applied AI — a combination that may determine how quickly the company's story gains traction with investors.